EICHOR
● Completed
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
Condition: Intracerebral Hemorrhage · Sponsor: Bioxodes S.A.
About this study
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (8)
| UZ Gent | Ghent, East Flanders, Belgium | — |
| UZ Leuven | Leuven, Flemish Brabant, Belgium | — |
| CHU Ambroise Paré | Mons, Hainaut, Belgium | — |
| AZ Sint-Jan | Bruges, West Flanders, Belgium | — |
| AZ Damiaan | Ostend, West Flanders, Belgium | — |
| UCL St Luc | Brussels, Belgium | — |
| UZ Brussel | Brussels, Belgium | — |
| Clinique CHC MontLégia | Liège, Belgium | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05970224